Overview

Safety and Tolerability of Odanacatib (0822-059)

Status:
Completed

Trial end date:
2010-05-02

Target enrollment:

Participant gender:

Summary

This study will test the weighted average inhibition of u-NTx/Cre (aminoterminal crosslinked telopeptide of Type 1 collagen) and AUC (0-168 hours) of Odanacatib

Phase:

Phase 1

Details

Lead Sponsor:

Merck Sharp & Dohme Corp.